'...............and given the clinical results so far, it does seem to outperform the competitors products. YEs, it will be tough to take market share from the well established competitors, but the product may just sell it self. remembering that every year of trials and early days of standard use, there will be a new cohort of trainee physicians who wont be as difficult to convince to chose AVR over the other.'
I have had this 'mind image' for some time.. USA of course. As time passes and our product gets the 'snowball effect':-
Patient---- needs urgent heart valve replacement . Advises Dr 'I want the top of the range valve' Dr----Uses one of the competitors.. Patient--- some time after then replacement finds that the valve - was not the 'top of the range' Starts to do some in depth research -with his Lawyer.
Use your imagination on the outcome, remembering -it is in the USA whose residents are born with some form of 'litigious ???' (my description )
In my opinion Doctors are becoming aware of our product................ have a look at those attending the seminars etc... we have.
Keep safe - pain before gain ?
AVR Price at posting:
$14.09 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)